#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma
Click to read the study in The Lancet Oncology.
Tag: Atezolizumab
#VisualAbstract: Atezolizumab may increase overall survival in patients with metastatic non-small-cell lung cancer
1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) ...
Atezolizumab may increase overall survival in patients with metastatic non-small-cell lung cancer
1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) ...
#VisualAbstract: Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma
1. Combination treatment of atezolizumab and bevacizumab was shown to significantly increase overall survival and progression-free survival outcomes in patients ...
Atezolizumab-bevacizumab treatment increases survival in unresectable hepatocellular carcinoma
1. Combination treatment of atezolizumab and bevacizumab was shown to significantly increase overall survival and progression-free survival outcomes in patients ...
Atezolizumab and nab-paclitaxel prolong progression-free survival for patients with metastatic triple-negative breast cancer: the IMpassion130 trial
1. This randomized controlled trial of women with metastatic triple-negative breast cancer reports that patients who were received atezolizumab with ...
